Peng Wang Named Scientific Chief Of Simcere Pharmaceutical
May 19, 2009 (FinancialWire) — Simcere Pharmaceutical Group (NYSE: SCR | Quote | Chart | News | PowerRating) has appointed Peng Wang as its chief scientific officer.
Wang most recently served as VP of discovery biology at WuXi PharmaTech (NYSE: WX). Before that he was a research fellow at Schering-Plough’s (NYSE: SGP) research institute, where he worked for eighteen years.
In his new role, Wang will lead Simcere’s research team in developing new products and research projects. He will also participate in the strategic planning of the R&D department and manage domestic and international research collaborations.
Nanjing, China-based Simcere Pharmaceutical is a manufacturer and supplier of branded generic and original pharmaceuticals in China. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication.
Simcere concentrates its research and development efforts on the treatment of diseases such as cancer, strokes, orthopaedics and infectious diseases.